| |
|
|
 |
 |
Nanogea Annonces that It Can Detect Prostate-Specific Antigens (PSA) at Unprecedented Levels
WESTLAKE VILLAGE, California, March 31, 2010 – Nanogea, a nano-biotechnology company focused on commercializing the industry’s most sensitive single molecular detection platform, is pleased to announce results regarding its Prostate Cancer diagnostic study.
In its first set of studies, Nanogea was able, with the use of its proprietary NanoCone-Enabled Atomic Force MicroscopyTM technology, to clearly differentiate Prostate-Specific Antigens (PSA) from the background and identify them at the level of individual molecules. |
| read more... |
Nanogea Featured in Scientific American
WESTLAKE VILLAGE, California, March 19th, 2010 – Nanogea, a nano-biotechnology company focused on commercializing the industry’s most sensitive single molecular detection platform, is pleased to announce that its technology was featured in an article by Scientific American, a prominent science and technology magazine.
The article "Seeing the Little Picture: Novel Nanocoating Gives Atomic Force Microscope Users a Better Look at Individual Molecules,” reports that Professor Ozgur Sahin, a Fellow at Harvard's Rowland Institute, has identified Nanogea’s Nanocone-Enabled Atomic Force MicroscopeTM (NE-AFMTM) approach as a way to help researchers spot diseases in its earliest stages. |
| read more... |
Nanogea Announces New Scientific Advisory Board Members
WESTLAKE VILLAGE, California, Oct. 9, 2009 Nanogea, a nano-biotech company focused on commercializing the industry’s most sensitive single molecular detection platform, is pleased to announce today that Dr. C. Thomas Caskey and Dr. Saul Tendler have joined its scientific advisory board.
Dr. Caskey is a prominent medical geneticist and biomedical entrepreneur. Dr. Caskey presently serves as Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, a research institute that seeks to investigate the cause of human diseases at the cellular and molecular levels using DNA and protein technologies to expose disease mechanisms. |
| read more... |
|
|
